Mimrylo earns FDA approval for Polycythemia Vera

The FDA has approved Mimrylo (rusfertide) from Takeda as a first-in-class hepcidin mimetic for adults with polycythemia vera, a condition causing excessive red blood cell production. By limiting iron availability, Mimrylo reduces red blood cell formation and keeps hematocrit under the safe 45% threshold, addressing a key limitation of current therapies. The approval was based on the Phase 3 VERIFY trial, which showed a majority of patients achieved clinical response and experienced reduced need for phlebotomy and improved fatigue, with acceptable tolerability primarily limited to injection-site reactions and anemia. Mimrylo provides a new option beyond phlebotomy, hydroxyurea, interferons, and Jakafi for patients whose PV is not well controlled, potentially lowering the treatment burden for many. Takeda and its collaborators anticipate global regulatory expansion and note that the approval does not alter the company's fiscal guidance, while investor timelines and stock activity reflect the regulatory milestone. PV affects about 90,000 people in the U.S., and a large share remain uncontrolled on existing therapies, highlighting Mimrylo’s potential to reshape PV management.